CD10 expression pattern in prostatic adenocarcinoma: Elucidation of differences between Gleason's grades

Area of Science:

• Oncology
• Uropathology
• Biomarker Research

Background:

• CD10, a transmembrane endopeptidase, is recognized for its potential loss during early prostate cancer development.
• Understanding CD10 expression patterns across different prostate cancer grades is crucial for diagnostic and prognostic insights.

Purpose of the Study:

• To investigate the expression patterns of CD10 in prostatic adenocarcinoma across various Gleason grades.
• To compare CD10 expression in prostate cancer with that in benign nodular hyperplasia of the prostate.
• To assess the potential utility of CD10 as a biomarker for prostate cancer stratification.

Main Methods:

• Retrospective analysis of 30 cases of nodular hyperplasia and 30 cases of prostatic adenocarcinoma.
• Immunohistochemical staining for CD10 was performed on all tissue samples.
• Evaluation of CD10 positivity included percentage of positive cells and subcellular localization (membranous, cytoplasmic, or both).

Main Results:

• CD10 positivity was significantly lower in prostatic adenocarcinoma compared to nodular hyperplasia.
• A notable decrease in CD10 expression was observed with increasing Gleason grade, with the lowest positivity in grade 5.
• The expression pattern shifted from predominantly membranous in lower grades to cytoplasmic in higher Gleason grades.

Conclusions:

• Loss of CD10 expression is associated with increasing tumor grade in prostate cancer.
• The observed changes in CD10 expression and localization correlate with tumor progression.
• CD10 may serve as a valuable biomarker for stratifying patients with prostate adenocarcinoma based on tumor grade.